A 48-year-old White man presented with chronic voiding problems. He was evaluated and found to have high urinary residuals ranging up to 1000 cc. He was started on alpha blockers but had persistent urinary retention. The upper urinary tracts were normal on ultrasound. Office cystoscopy showed no obvious pathology. Video-urodynamics were performed (see Figure 1…
Greater daily temperature differences, the average number of visits to emergency departments for lower urinary tract symptoms due to benign prostatic hyperplasia increase, according to a large study of Korean men.
Investigators found a significant positive correlation between transitional zone index (TZI) and IPSS and a significant negative correlation between TZI and both the International Index of Erectile Function and penile peak systolic velocity.
Aquablation therapy is associated with 3-year outcomes similar to those of transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia (BPH), according to a new study. At 3 years, men who underwent Aquablation—a minimally invasive procedure in which a high-velocity waterjet is used to resect…
Neutrophil-to-lymphocyte ratio (NLR) may be useful as a surrogate marker of intravesical prostatic protrusion (IPP) in men with benign prostatic hyperplasia, according to a new report. IPP is an anatomical feature caused by the growth of prostatic lateral and median lobes. The new finding is from a study of 250 men older than 50 years…
Prostate calcifications in men with benign prostatic hyperplasia are associated with nearly 3-fold increased odds of storage lower urinary tract symptoms and nocturia, a study found.
Men who have bladder outlet obstruction (BOO) prior to robotic-assisted radical prostatectomy experience significant worsening of lower urinary tract function compared with men without BOO, a study found.
In a prospective trial of men with erectile dysfunction and lower urinary tract symptoms, tadalafil plus tamsulosin achieved greater improvements in maximum urinary flow rates and voiding symptoms.
Post-marketing data show that prostatic urethral lift provides symptom relief in patients outside of the controlled clinical trial setting.
LUTS treatment with the alpha-blocker prazosin was associated with significantly lower 2- and 5-year biochemical recurrence rates vs tamsulosin and non-use of alpha-blockers.
